Streetbeat News

Regulatory

CYBN

Trading of Cybin shares has been temporarily halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 1:23 pm

MU

Micron shares are trading higher after the US Commerce Secretary reportedly discussed the company in meetings with China.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 1:06 pm

SUNW

Sunworks Inc has filed with the SEC to potentially offer and sell shares of its common stock up to a value of $17.6 million. The timing and amount of any sales will be determined by market conditions and other factors.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 1:06 pm

GOVX

GeoVax has received a notice of allowance for patent application No. 17/726,254 titled 'Compositions And Methods For Generating An Immune Response To Treat Or Prevent Malaria'. The patent covers a multiple component vaccine for both prevention and treatment of malaria.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 1:02 pm

HSAI

OUST

Ouster, Inc. (NYSE:OUST) has issued a statement regarding its ongoing patent infringement case against Hesai Group (NASDAQ:HSAI). The Administrative Law Judge recommended that the investigation be terminated to allow arbitrators time to decide whether Ouster is required to arbitrate based on a prior Settlement Agreement between Velodyne and Hesai. Ouster alleges that Hesai stole its patented technologies and incorporated them into competing products. The case is currently stayed pending the ITC investigation.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 1:01 pm

NVDA

NVIDIA Corporation (NASDAQ:NVDA) faces regulatory challenges in China, with the looming expiration of its permission to develop and export its H100 chip. Despite this, the company's stock recently hit an all-time high following a third consecutive revenue forecast surpassing Wall Street expectations. NVIDIA also expanded its partnership with VMware, unveiling a platform designed to facilitate the development and deployment of generative AI applications.

Portfolio Pulse from Mohit Manghnani

August 28, 2023 | 1:01 pm

INTC

MU

The U.S Commerce Chief has discussed Micron Technology Inc and Intel Corp with Chinese officials, according to Reuters. The discussions were part of a broader conversation about trade and investment between the two countries.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:58 pm

ABBV

AbbVie has submitted regulatory applications to the FDA and EMA for its drug Risankizumab, used in the treatment of ulcerative colitis. The submissions are backed by two Phase 3 clinical trials demonstrating the drug's effectiveness and safety. Risankizumab is currently approved by the FDA and EMA for Crohn's disease, psoriatic arthritis, and psoriasis.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:46 pm

SBET

SharpLink Gaming Ltd. (NASDAQ:SBET) CEO Rob Phythian issued a letter to shareholders outlining the company's growth strategies and key performance indicators. The company aims to have a profound impact on the U.S. sports betting industry by improving methods for reaching and converting sports fans into sports bettors. SharpLink has focused on acquiring an affiliate marketing company, completing a merger with SportsHub, and expanding its technology development team. The company's internal KPIs align with each component of its C4 solution: Connect, Collect, Convert, and Capitalize. SharpLink is licensed to operate in 24 U.S. states, the District of Columbia, Puerto Rico, and Ontario, Canada.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:38 pm

TTOO

T2 Biosystems, Inc. (NASDAQ:TTOO) has praised the U.S. Centers for Disease Control and Prevention's (CDC) new Hospital Sepsis Program Core Elements, aimed at improving sepsis programs and survival rates in U.S. hospitals. T2 Biosystems' products, including the T2Dx® Instrument, the T2Bacteria® Panel, and the T2Candida® Panel, are the first and only FDA-cleared products able to detect sepsis-causing pathogens directly from whole blood in 3-5 hours. The company's products identified sepsis-causing pathogens 77 hours faster than blood culture-based protocols, according to a meta-analysis of 14 controlled studies.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 12:37 pm